Skip to main content
. 2022 Mar 3;23(1):104–111. doi: 10.1080/15384047.2021.2011643

Figure 1.

Figure 1.

ARID family and its role in the pan-cancer analysis of cancer immunotherapy. a: The prevalence of genomic alterations in the ARID family; b: survival analysis based on genomic alterations in the ARID family in pan-cancer; c: the comparison of the overall survival status between the ARID mutated group and wild-type group; d: the comparison of tumor mutational burden (TMB) between the ARID mutated group and wild-type group; e: the comparison of mutation counts between the ARID mutated group and wild-type group.